Literature DB >> 17365919

A case of Kaposi's sarcoma following treatment of membranoproliferative glomerulonephritis and a review of the literature.

Kemal Agbaht1, Funda Pepedil, Alper Kirkpantur, Rahmi Yilmaz, Mustafa Arici, Cetin Turgan.   

Abstract

Kaposi's sarcoma (KS) is an unusual tumor principally affecting the skin of the lower extremities. Although the association between KS and renal transplant has been well documented, there are a few KS cases in the literature associated with membranoproliferative glomerulonephritis or other glomerular diseases. This report presents a patient with membranoproliferative glomerulonephritis (MPGN) who developed KS following treatment with long-term medium dose glucocorticoid and short-term additional immunosuppressives. The KS cases associated with glomerulonephritis are also reviewed. KS is a rare complication in glomerular diseases that may (or may not) be related to immunosuppression. Hence, immunosuppression treatment should be carefully planned in glomerulonephritis treatment and avoided if they are not essentially necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17365919     DOI: 10.1080/08860220601039551

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  3 in total

1.  Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin.

Authors:  Dmitri Wall; Mairín McMenamin; Deirdre O'Mahony; Alan D Irvine
Journal:  BMJ Case Rep       Date:  2013-11-21

2.  Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).

Authors:  V Ascoli; G Minelli; M Kanieff; R Crialesi; L Frova; S Conti
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

3.  Steroids are a risk factor for Kaposi's sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection.

Authors:  Mónica Fernández-Sánchez; María C Iglesias; Yuria Ablanedo-Terrazas; Christopher E Ormsby; Claudia Alvarado-de la Barrera; Gustavo Reyes-Terán
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.